## Abstract After single oral doses of 20 mg of a suspension of dihydralazine sulphate to human subjects, the peak of mean plasma concentrations of dihydralazine of 47Β·0 ng ml^β1^ Β± 11Β·0 standard deviation (S.D.) (__n__ = 7) was reached at 1 h. Mean concentrations declined biphasically with apparen
Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects
β Scribed by G. A. Baldock; R. R. Brodie; L. F. Chasseaud; T. Taylor; L. M. Walmsley; B. Catanese
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 540 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The pharmacokinetics of the antiβinflammatory drug benzydamine were determined after intravenous infusion of 5 mg to six healthy male subjects. Benzydamine was characterized as a drug of relatively low systemic clearance (ca. 160 ml min^β1^) but high volume of distribution (ca. 1101); the apparent terminal halfβlife in plasma was ca. 8h. Benzydamine was well absorbed after oral administration, as indicated by a mean systemic availability of 87 per cent. However, absorption of the drug was low (<10 per cent of the dose) after its use by male subjects as a mouthwash, or after its application to female subjects as dermal cream and vaginal douche preparations. The data suggest that benzydamine is generally not well absorbed through the skin and nonβspecialized mucosae, thereby limiting unrequired systemic exposure to this drug when it is used by these routes.
π SIMILAR VOLUMES
The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der
The pharmacokinetic properties of hydromorphone in healthy young male subjects were studied after i.v., peroral, and rectal administration. After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 k 0.5 h, hepatic extraction ratio 0.51, apparent volum
The objective of this single-dose study was to evaluate the pharmacokinetics and haemodynamic changes in healthy male subjects following the administration of three oral ( 5 , 15, and 40mg) and two intravenous (1 and 3mg) doses of felodipine, a new calcium antagonist with a selective effect on the p
Nicardipine HCI oral doses (10-40 mg) were administered sequentially to six healthy subjects. For each regimen the capsule dose was administered every 8 hours (q 8 h) for 3 days and the plasma profiles of nicardipine and its pyridine analogue (M5) were determined following the last dose on day 4. St